Literature DB >> 6270556

Defective EBV-specific suppressor T-cell function in rheumatoid arthritis.

G Tosato, A D Steinberg, R M Blaese.   

Abstract

Several lines of evidence, including high antibody titers to Epstein-Barr virus (EBV)-associated antigens and rapid transformation of B cells into lymphoblastoid cells lines, suggest an association between EBV and rheumatoid arthritis. When lymphocytes from normal immune donors were infected with EBV in culture, they produced an exponentially increasing number of immunoglobulin-secreting cells for eight to 10 days. Thereafter, there was a marked late suppression of their response, mediated by immunoregulatory T cells; by 12 days in culture, this suppression averaged 90 per cent. Lymphocytes from 20 EBV-immune patients with rheumatoid arthritis also responded with increasing production of immunoglobulin-secreting cells, but the late suppression expected in immune donors was absent. Tests of several other T-cell functions in these patients gave normal results, suggesting a more restricted defect in suppressor-T cell function relating specifically to EBV. Since EBV persists in host B cells and thus represents a potential stimulus for immunoglobulin production, this persistence, along with a specific regulatory T-cell defect, may contribute to many of the immune abnormalities underlying rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6270556     DOI: 10.1056/NEJM198111193052102

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  69 in total

Review 1.  Epstein-barr virus: environmental trigger of multiple sclerosis?

Authors:  Jan D Lünemann; Thomas Kamradt; Roland Martin; Christian Münz
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

2.  Epstein-Barr virus serologic abnormalities and risk of rheumatoid arthritis among women.

Authors:  Barbara L Goldstein; Lori B Chibnik; Elizabeth W Karlson; Karen H Costenbader
Journal:  Autoimmunity       Date:  2011-10-20       Impact factor: 2.815

3.  Infectious aspects and the etiopathogenesis of rheumatoid arthritis.

Authors:  Michal Kasher Meron; Howard Amital; Daniel Shepshelovich; Ori Barzilai; Maya Ram; Juan-Manuel Anaya; Roberto Gerli; Nicola Bizzaro; Bizzaro Nicola; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

4.  Spontaneous establishment of an Epstein-Barr virus-infected fibroblast line from the synovial tissue of a rheumatoid arthritis patient.

Authors:  J Koide; K Takada; M Sugiura; H Sekine; T Ito; K Saito; S Mori; T Takeuchi; S Uchida; T Abe
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  Evidence for oligoclonal B cell expansion in the peripheral blood of patients with rheumatoid arthritis.

Authors:  D A Fox; B R Smith
Journal:  Ann Rheum Dis       Date:  1986-12       Impact factor: 19.103

Review 6.  B cell clones in rheumatoid arthritis.

Authors:  M Steinitz
Journal:  Springer Semin Immunopathol       Date:  1988

7.  HLA-DR genotype risks in seropositive rheumatoid arthritis.

Authors:  L Legrand; G M Lathrop; A Marcelli-Barge; A Dryll; T Bardin; N Debeyre; J C Poirier; M Schmid; A Ryckewaert; J Dausset
Journal:  Am J Hum Genet       Date:  1984-05       Impact factor: 11.025

8.  Autoanti-idiotypes exhibit mimicry of myocyte antigens in virus-induced myocarditis.

Authors:  R E Paque; R Miller
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis.

Authors:  G Tosato; A D Steinberg; R Yarchoan; C A Heilman; S E Pike; V De Seau; R M Blaese
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

10.  Co-existence of acute myeloid leukemia with multilineage dysplasia and Epstein-Barr virus-associated T-cell lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report.

Authors:  Michihide Tokuhira; Kyoko Hanzawa; Reiko Watanabe; Yasunobu Sekiguchi; Tomoe Nemoto; Yasuo Toyozumi; Jun-ichi Tamaru; Shinji Itoyama; Katsuya Suzuki; Hideto Kameda; Shigehisa Mori; Masahiro Kizaki
Journal:  J Hematol Oncol       Date:  2009-06-30       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.